Construction of a Cuprotosis-Related Gene-Based Model to Improve the Prognostic Evaluation of Patients with Gastric Cancer

Figure 10

Potential drug screening. (a) AR-42 drug treatment effect. (b) Axitinib drug treatment effect. (c) Belinostat drug treatment effect. (d) BEZ235 drug treatment effect. (e) BMS345541 drug treatment effect. (f) Bortezomib drug treatment effect. (g) CAY10603 drug treatment effect. (h) CP466722 drug treatment effect. (i) CUDC-101 drug treatment effect. (j) Cytarabine drug treatment effect. (k) Elesclomol drug treatment effect. (l) GSK429286A drug treatment effect. (m) HG-6-64-1 drug treatment effect. (n) JW-7-24-1 drug treatment effect. (o) MG-132 drug treatment effect. (p) MLN4924 drug treatment effect.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)